Tenapanor administration and the activity of the H⁺ -coupled transporter PepT1 in healthy volunteers.

ABSTRACT:

Aim

Tenapanor (RDX5791/AZD1722), an inhibitor of gastrointestinal Na⁺ /H⁺ exchanger NHE3, is being evaluated for the treatment of patients with constipation-predominant irritable bowel syndrome and the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis. By reducing intestinal H⁺ secretion, inhibition of NHE3 by tenapanor could indirectly affect H⁺ -coupled transporter activity, leading to drug-drug interactions. We investigated the effect of tenapanor on the activity of the H⁺ -coupled peptide transporter PepT1 via assessment of the pharmacokinetics of cefadroxil - a compound transported by PepT1 - in healthy volunteers.

Methods

In this open-label, two-period crossover, phase 1 study (NCT

SUBMITTER: Johansson S 

PROVIDER: S-EPMC5582369 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature